Another group looked at gene expression levels of MECOM, ERG, WT1, GATA2, BAALC, MEIS1 and SPI1 in the bone marrow of 560 newly diagnosed AML patients and found that lower expression of MECOM and MEIS1 correlated with better CR rates, OS, and disease-free survival (DFS) [91]. The gene discussed is GATA2; the disease is acute myeloid leukemia.